A Novel Neutrophil-to-Lymphocyte Ratio and Sarcopenia Based TACE-Predict Model of Hepatocellular Carcinoma Patients
Shangyuan Wang,Xuanpu Zhang,Qi Chen,Zhi-Cheng Jin,Jian Lu,Jinhe Guo
DOI: https://doi.org/10.2147/JHC.S407646
2023-04-21
Journal of Hepatocellular Carcinoma
Abstract:Shangyuan Wang, Xuanpu Zhang, Qi Chen, Zhi-Cheng Jin, Jian Lu, Jinhe Guo Center of Interventional Radiology & Vascular Surgery, Department of Radiology, Zhongda Hospital, Medical School, Southeast University, Nanjing, 210009, People's Republic of China Correspondence: Jian Lu; Jinhe Guo, Center of Interventional Radiology & Vascular Surgery, Department of Radiology, Zhongda Hospital, Southeast University, 87 Dingjiaqiao Road, Nanjing, 210009, People's Republic of China, Tel +86-25-83262230 ; +86-25-83272121, Email ; Purpose: Transarterial chemoembolization (TACE) was commonly applied in hepatocellular carcinoma (HCC) patients across BCLC A-C stages with heterogeneous outcomes in real-world practice. We aimed to develop a neutrophil-to-lymphocyte ratio (NLR) and sarcopenia-based prognostic nomogram to estimate the prognosis of HCC patients after TACE treatment. Patients and Methods: Between June 2013 and December 2019, a total of 364 HCC patients who underwent TACE were included and randomly assigned to the training (n=255) and the validation cohort (n=109). Sarcopenia was diagnosed based on the third lumbar vertebra skeletal muscle mass index (L3-SMI). The multivariate Cox proportional risk model was used to generate a nomogram. Results: NLR ≥ 4.0, sarcopenia, alpha-fetoprotein (AFP) ≥ 200 ng/mL, albumin-bilirubin (ALBI) grade 2 or 3, number of lesions (≥ 2), and maximum size of the lesion (≥ 5 cm) were independent predictors for overall survival (OS) (P < 0.05). The calibration curve shows that the predicted results agree well with the observed results. The time-dependent areas under the receiver-operating characteristic curves for OS at 1, 2, and 3 years predicted by the nomogram were 0.818/0.827, 0.742/0.823, and 0.748/0.836 in both training and validation cohorts. Nomogram can divide patients into low-, medium- and high-risk groups based on predictor factors. The C-indexes of the nomogram for OS were 0.782/0.728 in the training and validation cohorts, outperforming other currently available models. Conclusion: A novel nomogram based on NLR and sarcopenia may be useful to predict the prognosis of HCC patients who underwent TACE across BCLC A-C stage patients. Keywords: hepatocellular carcinoma, transarterial chemoembolization, neutrophil-to-lymphocyte ratio, sarcopenia, albumin-bilirubin, nomogram Hepatocellular carcinoma (HCC) is the sixth most common cancer and the third leading cause of cancer-related death in 2020 worldwide. 1,2 According to the recommendation of the Barcelona Clinical Liver Cancer (BCLC) staging system, transarterial chemoembolization (TACE) is the first choice for the treatment of intermediate-stage HCC. 3 The BRIDGE study based on real-world data found that the first treatment of HCC patients across all stages was most frequently transarterial chemoembolization in North America, Europe, China, and South Korea 4 . Meanwhile, because the nature of HCC is highly heterogeneous, not all HCC patients can benefit from TACE. Therefore, predictor tools of overall survival (OS) can be helpful in clinical decision-making. 4,5 So far, various prognostic models have been developed to predict survival after TACE, including the HAP score, 6 ALBI-TAE score, 7 and six-and-twelve score. 8 These models were based on routinely available parameters, including tumor factors (tumor number and maximum size), alpha-fetoprotein (AFP) level, and bilirubin. However, most of these models were built to predict prognosis after TACE in BCLC A or B stage patients, while BCLC-C stage patients were excluded. Recently, increasing evidence showed that systemic inflammation plays a vital role in tumor progression and the long-term prognosis of patients with established cancers. 9 The neutrophil-to-lymphocyte ratio (NLR) is a readily available systemic inflammatory marker associated with cancer progression. High NLR has been proven to be related to poor prognosis of cancer, including hepatocellular carcinoma. 10–12 Systemic inflammation can also accelerate metabolism and make patients' nutritional status worse. 13 As a reflection of nutritional status, sarcopenia is a progressive and generalized skeletal muscle disorder characterized by accelerated loss of muscle mass and function. It is a common syndrome in aging patients with chronic disorders. Sarcopenia increases the risk of falls and fractures, causes an impaired ability to perform activities of daily living, and leads to a lower quality of life, even death. 14,15 Patients with chronic diseases showed higher prevalence rates of sarcopenia: 29.7% in cardioVascular disease, 24% in chronic obstructive pulmonary disease, and 48.1% in liver cirrhosis. 16 -Abstract Truncated-
oncology